Cited 7 times in
A hierarchical prognostic model for risk stratification in patients with early breast cancer according to 18 F-fludeoxyglucose uptake and clinicopathological parameters
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김동우 | - |
dc.contributor.author | 김민정 | - |
dc.contributor.author | 김현정 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 조영업 | - |
dc.contributor.author | 차종태 | - |
dc.date.accessioned | 2018-11-16T16:53:46Z | - |
dc.date.available | 2018-11-16T16:53:46Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165444 | - |
dc.description.abstract | This study was to investigate a hierarchical prognostic model using clinicopathological factors and 18 F-fludeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) for recurrence-free survival (RFS) in patients with early breast cancer who underwent surgery without neoadjuvant chemotherapy. A total of 524 patients with early breast cancer were included. The Cox proportional hazards model was used with clinicopathological variables and maximum standardized uptake value (SUVmax) on PET/CT. After classification and regression tree (CART) modeling, RFS curves were estimated using the Kaplan-Meier method and differences in each risk layer were assessed using the log-rank test. During a median follow-up of 46.2 months, 31 (5.9%) patients experienced recurrence. The CART model identified four risk layers: group 1 (SUVmax ≤6.75 and tumor size ≤2.0 cm); group 2 (SUVmax ≤6.75 and Luminal A [LumA] or TN tumor >2.0 cm); group 3 (SUVmax ≤6.75 and Luminal B [LumB] or human epidermal growth factor receptor 2 [HER2]-enriched] tumor >2.0 cm); group 4 (SUVmax >6.75). Five-year RFS was as follows: 95.9% (group 1), 98% (group 2), 82.8% (group 3), and 85.4% (group 4). Group 3 or group 4 showed worse prognosis than group 1 or group 2 (group 1 vs. group 3: P = 0.040; group 1 vs. group 4: P < 0.001; group 2 vs. group 3: P = 0.016; group 2 vs. group 4: P < 0.001). High SUVmax (>6.75) in primary breast cancer was an independent factor for poor RFS. In patients with low SUVmax, LumB or HER2-enriched tumor >2 cm was also prognostic for poor RFS, similar to high SUVmax. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | A hierarchical prognostic model for risk stratification in patients with early breast cancer according to 18 F-fludeoxyglucose uptake and clinicopathological parameters | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | Jongtae Cha | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Dongwoo Kim | - |
dc.contributor.googleauthor | Hyun Jeong Kim | - |
dc.contributor.googleauthor | Min Jung Kim | - |
dc.contributor.googleauthor | Young Up Cho | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1002/cam4.1394 | - |
dc.contributor.localId | A05304 | - |
dc.contributor.localId | A00473 | - |
dc.contributor.localId | A01129 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A05420 | - |
dc.contributor.localId | A04801 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 29479851 | - |
dc.subject.keyword | 18F-FDG PET/CT | - |
dc.subject.keyword | classification and regression tree modeling | - |
dc.subject.keyword | early breast cancer | - |
dc.subject.keyword | recurrence-free survival | - |
dc.subject.keyword | risk model | - |
dc.contributor.alternativeName | Kim, Dongwoo | - |
dc.contributor.alternativeName | Kim, Min Jung | - |
dc.contributor.alternativeName | Kim, Hyun Jeong | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.alternativeName | Cho, Young Up | - |
dc.contributor.alternativeName | Cha, Jongtae | - |
dc.contributor.affiliatedAuthor | 김동우 | - |
dc.contributor.affiliatedAuthor | 김민정 | - |
dc.contributor.affiliatedAuthor | 김현정 | - |
dc.contributor.affiliatedAuthor | 박형석 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 조영업 | - |
dc.contributor.affiliatedAuthor | 차종태 | - |
dc.citation.volume | 7 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1127 | - |
dc.citation.endPage | 1134 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.7(4) : 1127-1134, 2018 | - |
dc.identifier.rimsid | 58908 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.